Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma.
about
Lung cancer signatures in plasma based on proteome profiling of mouse tumor modelsSoluble Epidermal Growth Factor Receptors (sEGFRs) in Cancer: Biological Aspects and Clinical RelevanceEGFR ligands exhibit functional differences in models of paracrine and autocrine signalingShoc2 is targeted to late endosomes and required for Erk1/2 activation in EGF-stimulated cellsThe influence of radiographic phenotype and smoking status on peripheral blood biomarker patterns in chronic obstructive pulmonary disease.Diagnostic value of epidermal growth factor, cancer antigen 125, and cancer antigen 15-3 in bronchoalveolar lavage fluid of lung cancer.Clinical significance of EGFR, Her-2 and EGF in oral squamous cell carcinoma: a case control studyActivation of diverse signalling pathways by oncogenic PIK3CA mutations.Smokers with CT detected emphysema and no airway obstruction have decreased plasma levels of EGF, IL-15, IL-8 and IL-1ra.Potential of soluble CD26 as a serum marker for colorectal cancer detection.Sensitive targeted quantification of ERK phosphorylation dynamics and stoichiometry in human cells without affinity enrichment.Protein shedding in urothelial bladder cancer: prognostic implications of soluble urinary EGFR and EpCAM.Pretreatment levels of the serum biomarkers CEA, CYFRA 21-1, SCC and the soluble EGFR and its ligands EGF, TGF-alpha, HB-EGF in the prediction of outcome in erlotinib treated non-small-cell lung cancer patientsSoluble epidermal growth factor receptor (sEGFR) and carcinoembryonic antigen (CEA) concentration in patients with non-small cell lung cancer: correlation with survival after erlotinib and gefitinib treatment.Serum calprotectin, CD26 and EGF to establish a panel for the diagnosis of lung cancerPreliminary Evidence on the Diagnostic and Molecular Role of Circulating Soluble EGFR in Non-Small Cell Lung Cancer.Epidermal growth factor-like growth factors in the follicular fluid: role in oocyte development and maturationDifferent Epidermal Growth Factor Receptor (EGFR) Agonists Produce Unique Signatures for the Recruitment of Downstream Signaling ProteinsOncogene and tumor-suppressor gene products as serum biomarkers in occupational-derived lung cancer.Functional selectivity of EGF family peptide growth factors: implications for cancer.Systems-level interactions between insulin-EGF networks amplify mitogenic signaling.Epidermal growth factor (EGF) receptor-ligand based molecular staging predicts prognosis in head and neck squamous cell carcinoma partly due to deregulated EGF- induced amphiregulin expression.Splice Variants of the RTK Family: Their Role in Tumour Progression and Response to Targeted Therapy.Extracellular domain shedding influences specific tumor uptake and organ distribution of the EGFR PET tracer 89Zr-imgatuzumabHuman urine proteomics: building a list of human urine cancer biomarkers.Amphiregulin as a Novel Serum Marker of Puberty in Girls.Integrative meta-modeling identifies endocytic vesicles, late endosome and the nucleus as the cellular compartments primarily directing RTK signaling.Bioactive factors in milk across lactation: Maternal effects and influence on infant growth in rhesus macaques (Macaca mulatta).Mathematical simulations for bioanalytical assay development: the (un-)necessity and (im-)possibility of free drug quantification.Serum epidermal growth factor receptor levels in patients with malignant melanoma.Epidermal growth factor receptor detection in serum and saliva as a diagnostic and prognostic tool in oral cancer.Complement Component 3 Adapts the Cerebrospinal Fluid for Leptomeningeal Metastasis.Photo-immobilized EGF chemical gradients differentially impact breast cancer cell invasion and drug response in defined 3D hydrogels.
P2860
Q24628852-FCA6B208-12A4-4301-AADC-21B89B420113Q26750970-59F47AE4-8F78-4636-8CAF-F9BD72B6D5CFQ26864769-EA6C08D3-9806-4EDB-9309-2DACF76A70D4Q27303629-D740BC06-689A-4AC3-9876-2E377512E0E4Q33498530-78489EDE-E916-4C8F-8BED-48741DF51268Q33840163-851E3540-3CB0-406E-B0B6-1588EB31298DQ33878700-515287C9-CB6A-48AE-8598-B95119B66305Q34408364-9E83E1C1-D897-47D8-A15B-C7425400528BQ34663701-D25B535D-BBBB-4614-97A1-2201DF35B951Q35113393-A02C8F49-F167-4D0B-8F77-9A11084910ACQ35193821-1EDC62DF-B7C9-4558-8E6D-AA43F285DE46Q35198309-32C1D969-F034-4FBB-9D61-325C317713F6Q35478632-216C174B-42B9-4D92-AB05-3196998BAC39Q35602124-506813A9-E39E-4D55-A490-7D6D4BCB3192Q35620753-613764CA-5E57-41D6-9689-544C904BA3E8Q36088722-7770D419-D729-4F48-B2A9-5A4B5CAABFFBQ36219314-7E3F015A-6D6F-4B34-8470-1F3BD0087973Q36674591-D6578529-E811-40DA-8F25-9559677617D3Q36950436-85E313BE-1710-44FB-99C0-903E7E8330FAQ37149729-137C3DDE-27C8-4F11-8943-4FF54F01C101Q37196175-1C8E4229-BE3E-47D0-8DE9-A752E970701FQ37286023-07C92DF9-89A7-4235-8CE1-EE7F14B850A8Q37690917-5E8F5FAB-F8AE-4337-A98E-ACF63ABC5F5EQ37708758-915D80E7-4858-458F-9C1C-6857CDA78BA6Q37890422-73591AE1-2623-4043-B687-5F8BF7758025Q40328183-9FBB6489-4BD2-4F56-8F39-7A477D5B3D7DQ40463360-286AD00B-E987-450A-9A4B-4605C4DD303EQ41201123-9C12C470-701E-442A-A28C-16470709F97BQ44542878-20CDE5B1-7B1B-489F-9AAD-D4D2A3275057Q46840133-490B3B14-28A6-4C68-9CFA-A87FAEEA2F26Q47985329-1DB922FB-B860-4093-90D7-027CDC094CCBQ48269323-CC1F9B57-40C3-4D0D-B91D-010CEC5C1A3CQ49918151-3E790A0E-B169-46E7-A2F4-27EADEFA3CC4
P2860
Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Alteration of the serum levels ...... r and head and neck carcinoma.
@ast
Alteration of the serum levels ...... r and head and neck carcinoma.
@en
type
label
Alteration of the serum levels ...... r and head and neck carcinoma.
@ast
Alteration of the serum levels ...... r and head and neck carcinoma.
@en
prefLabel
Alteration of the serum levels ...... r and head and neck carcinoma.
@ast
Alteration of the serum levels ...... r and head and neck carcinoma.
@en
P2093
P2860
P356
P1476
Alteration of the serum levels ...... er and head and neck carcinoma
@en
P2093
F J Rodríguez-Berrocal
M Páez de la Cadena
Y Lemos-González
P2860
P2888
P304
P356
10.1038/SJ.BJC.6603770
P407
P50
P577
2007-04-24T00:00:00Z